Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R.
机构：[1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.临床科室其他部门内科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[2]State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, 510623, China
第一作者机构：[1]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
共同第一作者：
通讯作者：
通讯机构：[*1]No. 651, Dongfeng East Road, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
推荐引用方式(GB/T 7714)：
Mei-ting Chen,Zhao Wang,Meng Yuan,et al.Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R.[J].LUNG CANCER.2020,doi:10.1016/j.lungcan.2020.03.018.
APA：
Mei-ting Chen,Zhao Wang,Meng Yuan,Xiao-jie Fang&Tong-yu Lin.(2020).Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R..LUNG CANCER,,
MLA：
Mei-ting Chen,et al."Treatment of pembrolizumab and chemotherapy results in pulmonary lymphoepithelioma-like carcinoma progression through harboring secondary amplification of PI3KCA and IL-7R.".LUNG CANCER .(2020)
